Furthermore, some of the current cancer treatments can boost the overproduction of endogenous Flt3L, such as radiation therapy and some chemotherapeutic agents.36 Indeed, our preclinical data establish the proof-of-principle for a combined chemo-immunotherapy based on cyclophosphamide in a DNGR-1-deficient setting. Here, CLEC9A is linked to cancer.